BioCentury | Mar 2, 2021
Deals
WuXi looks to plasmid-free gene therapy manufacturing with Oxgene acquisition
...in Shanghai over the past two and half years.WuXi ATU’s CEO David Chang told BioCentury Oxford Genetics Ltd.’s AAV...
...Genuity; these three firms own more than 80% of the company. Karen Tkach Tuzman WuXi AppTec Co. Ltd. Oxford Genetics Ltd. gene...
...Genuity; these three firms own more than 80% of the company. Karen Tkach Tuzman WuXi AppTec Co. Ltd. Oxford Genetics Ltd. gene...